BHVN Stock Analysis: Biohaven | NYSE

Biotechnology | NYSE, USA | Market Cap: 2.403m USD | 12M Return: 12.8% | Charts, Fundamentals & Technical Analysis

Immunology, Neuroscience, Oncology, Biopharmaceuticals
Total Rating 37
Safety 78
Buy Signal 0.45
Biotechnology
Industry Rotation: +30.9
Market Cap: 2.40B
Avg Turnover: 49.8M
Risk 3d forecast
Volatility79.1%
VaR 5th Pctl11.6%
VaR vs Median-8.68%
Reward TTM
Sharpe Ratio0.57
Rel. Str. IBD84.2
Rel. Str. Peer Group45.8
Character TTM
Beta1.804
Beta Downside1.747
Hurst Exponent0.511
Drawdowns 3y
Max DD86.96%
CAGR/Max DD-0.16
CAGR/Mean DD-0.31
EPS (Earnings per Share) EPS (Earnings per Share) of BHVN over the last years for every Quarter: "2021-06": -3.23, "2021-09": -2.63, "2021-12": -3.01, "2022-03": -2.97, "2022-06": -6.21, "2022-09": -1.75, "2022-12": -3.32, "2023-03": -1.03, "2023-06": -1.32, "2023-09": -1.5, "2023-12": -1.81, "2024-03": -2.2, "2024-06": -3.5, "2024-09": -1.74, "2024-12": -1.71, "2025-03": -2.17, "2025-06": -1.94, "2025-09": -1.64, "2025-12": -0.9, "2026-03": -0.69,
Last SUE: 0.54
Qual. Beats: 0
Revenue Revenue of BHVN over the last years for every Quarter: 2021-06: 92.933, 2021-09: 135.74, 2021-12: 190.013, 2022-03: 318.852, 2022-06: 215.079, 2022-09: 0, 2022-12: -215.079, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 3.836, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: 0,
Last SUE: 0.00
Qual. Beats: 0

Warnings

Strong Share Dilution
Altman Z'' In Financial Distress Zone

Tailwinds

Supp Ema8

Seasonality 3.8 years of data

Jan +2.5% 32
Feb -0.1% 11
Mar -24.6% 16
Apr -6.2% 12
May -14.7% 13
Jun -1.0% 12
Jul +9.0% 34
Aug +0.0% 0
Sep +19.6% 36
Oct +6.6% 13
Nov -9.4% 12
Dec +13.5% 18

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: BHVN Biohaven

Biohaven Ltd. (NYSE: BHVN) is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes therapies across immunology, neuroscience, and oncology. The firm was incorporated in 2022 and is headquartered in New Haven, Connecticut, having previously operated as Biohaven Research Ltd. It is listed as a mid-cap stock in the GICS Biotechnology sub-industry, reflecting its clinical-stage profile rather than current revenue generation from approved products.

The companys pipeline spans all major phases of clinical development, anchored by two Phase 3 candidates: BHV-8000 for Parkinsons disease and Opakalim for focal epilepsy. Its Phase 2 programs cover a broad range of indications, including BHV-1300 for Graves disease and rheumatoid arthritis, BHV-1400 for IgA nephropathy, BHV-1510 for advanced epithelial tumors, and BHV-1530 for urothelial cancer, while BHV-1600 (peripartum cardiomyopathy) and BHV-2100 (pain disorders) are among its earlier-stage assets. As a clinical-stage biotech, Biohavens value is tied to pipeline progression outcomes, with commercialization typically years away for most candidates.

In addition to its clinical assets, Biohaven maintains a wide preclinical portfolio targeting diseases such as myasthenia gravis, type 1 diabetes, neurodegenerative diseases, and tinnitus. Like most early-stage biopharma peers, the company relies on capital markets and R&D partnerships to fund its multi-year drug development programs, with the bulk of its near-term value drivers concentrated in the Phase 2 and Phase 3 readouts.

Headlines to Watch Out For
  • BHV-8000 Phase 3 Parkinsons readout approaches
  • Opakalim Phase 3 epilepsy data catalyst ahead
  • Cash burn rises funding multiple late-stage trials
Piotroski VR-10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -1.18 > 0.02 and ΔFCF/TA 55.20 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -1.27 > 3% & CFO -594.2m > Net Income -647.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.41 > 1.5 & < 3
Outstanding Shares: last quarter (147.6m) vs 12m ago 44.80% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.84%; Δ -0.84% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.72 (Total Current Assets 385.6m - Total Current Liabilities 52.1m) / Total Assets 466.4m
B: -4.75 (Retained Earnings -2.22b / Total Assets 466.4m)
C: -1.40 (EBIT TTM -646.6m / Avg Total Assets 462.7m)
D: 0.38 (Book Value of Equity 129.5m / Total Liabilities 336.9m)
Altman-Z'' = -19.78 = D
What is the price of BHVN shares?

As of July 08, 2026, the stock is trading at USD 15.55 with a total of 2,694,796 shares traded. Over the past week, the price has changed by +4.01%, over one month by +39.84%, over three months by +67.93% and over the past year by +12.76%.

Current recommended Stop Loss: 12.60 (which is 19% or 2.9 ATR below the current price).

Is BHVN a buy, sell or hold?

Biohaven has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy BHVN.

  • StrongBuy: 11
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the BHVN price?
Analysts Target Price 21.9 41.1%
Biohaven (BHVN) - Fundamental Data Overview as of 06 July 2026
Market Cap USD = 2.40b (2.40b USD * 1.0 USD.USD)
P/B = 18.3231
Revenue TTM = 0.0 USD
EBIT TTM = -646.6m USD
EBITDA TTM = -638.5m USD
Long Term Debt = 241.9m USD (from longTermDebt, last quarter)
Short Term Debt = 5.90m USD (from shortTermDebt, last quarter)
Debt = 330.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 44.3m
Net Debt = -17.4m USD (calculated: Debt 330.4m - CCE 347.8m)
Enterprise Value = 2.39b USD (2.40b + Debt 330.4m - CCE 347.8m)
 Interest Coverage Ratio = unknown (Ebit TTM -646.6m / Interest Expense TTM 0.0)
 EV/FCF = -4.34x (Enterprise Value 2.39b / FCF TTM -550.3m)
FCF Yield = -23.07% (FCF TTM -550.3m / Enterprise Value 2.39b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.14m) / Revenue TTM)
 Tobins Q-Ratio = 5.11 (Enterprise Value 2.39b / Total Assets 466.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 330.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -510.8m (EBIT -646.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.17 (Total Current Assets 385.6m / Total Current Liabilities 62.5m)
Debt / Equity = 2.55 (Debt 330.4m / totalStockholderEquity, last quarter 129.5m)
 Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -17.4m / EBITDA -638.5m)
 Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -17.4m / FCF TTM -550.3m)
 Total Stockholder Equity = 74.7m (last 4 quarters mean from totalStockholderEquity)
 RoA = -140.0% (out of range, set to none)
 RoE = -866.5% (Net Income TTM -647.7m / Total Stockholder Equity 74.7m)
 RoCE = -204.2% (out of range, set to none) (EBIT -646.6m / Capital Employed (Equity 74.7m + L.T.Debt 241.9m))
 RoIC = -121.6% (out of range, set to none) (NOPAT -510.8m / Invested Capital 420.2m)
 WACC = 10.84% (E(2.40b)/V(2.73b) * Re(12.33%) + D(330.4m)/V(2.73b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 31.34%
 [DCF] Fair Price = unknown (Cash Flow -550.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.54 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.61 | Chg30d=+4.33% | Revisions=+0% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.57 | Chg30d=+3.11% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.40 | Chg30d=+3.28% | Revisions=+0% | GrowthEPS=+56.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.95 | Chg30d=+0.17% | Revisions=+12% | GrowthEPS=+18.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +4% (up=12, down=11)